Medfield Pharmaceuticals Case Analysis
Name
Course
Date
, MEDFIELD PHARMACEUTICALS CASE ANALYSIS 2
Medfield Pharmaceuticals Case Analysis
Summary of the case
The presented case attempts to evaluate the feasibility of the development of a new drug
by Medfield Pharmaceuticals company. This case addresses two significant issues related to the
financial viability of the project and the ethics concern. On an economic standpoint, the case
requires the valuation of the company's current worth and how the development of the new drug
will affect the financial results. The ethics standpoint, on the other hand, represents the
company's moral obligation to alleviate the patient's suffering by developing the new drug.
Case analysis
The current value of Medfield Pharmaceuticals
The current value of the Medfield Pharmaceuticals company taking into account the
amount of the net operating profit after taxes is of $338.81. This value considers the calculated
NOPAT values for the period 2010-2019 reported in exhibit 4 and a discount rate of 8.5%. The
calculation is:
Research 19.0%
Direct marketing 27.0%
General and admin. 4.0%
Taxes 32.0%
Discount rate 8.5%
2,010 2,011 2,012 2,013 2,014 2,015
Fleximat
Sales $ 210.56 $ 214.77 $ 219.07 $ 109.53 $ 54.77 $ 27.38
Cost of sales $ 47.46 $ 49.40 $ 50.39 $ 25.19 $ 12.60 $ 6.30
Lodamadal
Sales $ 39.67 $ 40.47 $ 41.28 $ 42.10 $ 42.94 $ 43.80
Cost of sales $ 10.55 $ 9.31 $ 9.49 $ 9.68 $ 9.80 $ 10.07
Orsamorph
Sales $ 78.97 $ 80.55 $ 82.16 $ 83.80 $ 85.48 $ 87.19
Cost of sales $ 18.46 $ 18.53 $ 18.90 $ 19.27 $ 19.66 $ 20.05
Reximet
Sales $ 80.00 $ 81.60 $ 83.23 $ 84.90
Cost of sales $ 18.40 $ 18.77 $ 19.14 $ 19.53